Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia

Blood Adv (2023) 7 (3): 396–405.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals